← Trials/Trial dossier/NCT01433666

EEGrofl

CompletedPhase 2

Roflumilast and Cognition

Effects of Roflumilast on Cognition in Healthy Adults: a Behaviour-EEG Study

Lead sponsor

Maastricht University Medical Center

Asset

Roflumilast

Listed sites

Recruiting sites

Enrollment

actual

Study population

Mixed / unspecified dementia

Key I/E criterion

•Age 18-35

Primary endpoint

•Number of words remembered on Verbal learning task

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Eudract number2011-002070-23

Org study IDMETC11-3-035

NCT IDNCT01433666

Other grantZonMw (the Netherlands)95110091

Timeline

Milestones

Study start2011-09 (month precision)

Study first posted2011-09-14estimated

Primary completion2012-07actual (month precision)

Study completion2013-09actual (month precision)

Last update posted2020-01-02actual

Assets

Drug assets

Roflumilast

Study populations

Who this study enrolls

Mixed / unspecified dementia

Eligibility

Who can enroll

Minimum age18 Years

Maximum age35 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•18 to 35 years of age

•Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected),

•Body mass index between 18.5 and 30

•Willingness to sign an informed consent.

•Positive evaluation on the memory screening

Exclusion criteria

•History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness

•First-degree relative with psychiatric disorder (in particular major depressive disorder and suicidality)

•Excessive drinking (>20 glasses of alcohol containing beverages per week)

•Pregnancy or lactation

•Use of chronic medication other than oral contraceptives

•Use of recreational drugs in the 2 weeks preceding participation

•Smoking

•Orthostatic hypotension

•Lactose intolerance

•Sensory or motor deficits which could reasonably be expected to affect test performance

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Memory

1 endpoint

Primary/protocol endpoint

Number of words remembered on Verbal learning task

Time frame:1hr after drug intake

event count, event

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.